Gilead Sciences, Inc. (GILD)

61.60 -1.19 (-1.90%) As of 10:31AM EST. Market open.

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
http://www.gilead.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Daniel P. O'Day	Chairman & CEO	10.86M	N/A	1964
Mr. Andrew D. Dickinson	Exec. VP & CFO	6.91M	N/A	1970
Mr. Brett A. Pletcher	Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.	2.14M	1.84M	1968
Ms. Johanna Mercier	Chief Commercial Officer	2.55M	N/A	1970
Dr. Merdad V. Parsey M.D., Ph.D.	Chief Medical Officer	1.12M	N/A	1964
Ms. Diane E. Wilfong	Sr. VP, Corp. Controller & Chief Accounting Officer	N/A	N/A	1962
Ms. Jyoti K. Mehra	Exec. VP of HR	N/A	N/A	N/A
Dr. William A. Lee	Exec. VP of Research	N/A	N/A	1955
Dr. Taiyin Yang	Exec. VP of Pharmaceutical Devel. & Manufacturing	N/A	N/A	1954
Dr. Diana M. Brainard M.D.	Sr. VP of HIV & Emerging Viral Infections	N/A	N/A	1972

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; Roche Holding AG; and Vir Biotechnology, Inc. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.

Corporate governance

Gilead Sciences, Inc.’s ISS governance QualityScore as of 2 December 2020 is 4. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 2; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.